Title

Ferritin Screening And IRon Treatment for Maternal Anemia and FGR Prevention Trial
Ferritin Screening And IRon Treatment for Maternal Anemia and Fetal Growth Restriction (FGR) Prevention - a Multi Centre Randomised Controlled Trial (RCT)
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Active, not recruiting
  • Study Participants

    600
Prevalence of anemia in Asia is more than 50%. All woman who book for antenatal care with non-anaemic iron deficiency (NAID) can be offered therapeutic doses of parentral iron, as a directly observed complete therapy, to prevent of maternal anaemia and fetal growth restriction. The investigators will compare this intervention with usual care in a multicentre randomised trial.
Prevalence of anemia (haemoglobin less than 11 gm/dl) in Asia is more than 50% and non-anaemic iron deficiency (ferritin less than 30 microgm/l) or NAID is likely to be more prevalent than this figure. It has been hypothesised that NAID in pregnancy can be linked to maternal fatigue and anaemia, and infant birth weight and growth restriction. The investigators will compare, in NAID, active intervention (therapeutic doses of parentral iron, as a directly observed complete therapy, to replenish iron stores) vs usual care (prophylactic oral iron supplementation) to prevent of maternal anaemia and fetal growth restriction in a multicentre randomised trial.
Study Started
Aug 01
2020
Primary Completion
Jan 30
2024
Anticipated
Study Completion
Feb 28
2024
Anticipated
Last Update
Dec 21
2023

Drug Parentral Iron

Correction of Iron stores without anaemia

Treatment Active Comparator

Intravenous Iron to correct Iron deficiency without anaemia

Prophylaxis No Intervention

Usual antenatal care

Criteria

Inclusion Criteria:

Non-anaemic iron deficiency

Exclusion Criteria:

Anaemia or normal iron stores
No Results Posted